CROI 2017 Program and Information

Program and Agenda

44LB PHASE III SWORD 1&2: SWITCH TO DTG+RPVMAINTAINS 10:30 VIROLOGIC SUPPRESSION THROUGH48WKS Josep M. Llibre 1 , Chien-Ching Hung 2 , Cynthia Brinson 3 , Francesco Castelli 4 , Pierre-Marie Girard 5 , Lesley Kahl 6 , Elizabeth Blair 7 , Brian Wynn 8 , Kati Vandermeulen 9 , Michael Aboud 7 1 Univ Hosp Germans Trias, Badalona, Barcelona, Spain, 2 Natl Taiwan Univ Hosp, Taipei, Taiwan, 3 Central Texas Clinical Rsr, Austin, TX, USA, 4 ASST Spedali Civili di Brescia, Brescia, Italy, 5 Saint-Antoine Hosp, Paris, France, 6 ViiV Hlthcare, Brentford, Middlesex, UK, 7 ViiV Hlthcare, Rsr Triangle Park, NC, USA, 8 ViiV Hlthcare, Collegeville, PA, USA, 9 Janssen, Beerse, Belgium 45LB DORAVIRINE IS NON-INFERIOR TO DARUNAVIR/R IN PHASE 3 11:45 TREATMENT-NAÏVE TRIAL ATWEEK 48 Jean-Michel Molina 1 , Kathleen Squires 2 , Paul E. Sax 3 , Pedro Cahn 4 , Johan Lombaard 5 , Edwin DeJesus 6 , Xia Xu 7 , Bach-Yen T. Nguyen 7 , George Hanna 7 , Carey Hwang 7 1 Hosp St Louis, Paris, France, 2 Thomas Jefferson University, Philadelphia, PA, USA, 3 Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA, 4 Fundación Huesped, Buenos Aires, Argentina, 5 Josha Research, Bloemfontein, South Africa, 6 Orlando Immunology Center, Orlando, FL, USA, 7 Merck & Co, Inc, Kenilworth, NJ, USA Themed Discussion TD-1: CD8 T CELLS: WHERE AND HOW THEY KILL Room 615-617 1:30 PM - 2:30 PM Themed Discussion Leader Nicole Frahm, FHCRC, Seattle, WA, USA 266 LYMPHNODE HIV-SPECIFIC CXCR5+CTLs ARE ASSOCIATEDWITH ENHANCEDVIRAL CONTROL Zaza Ndhlovu 1 , Funsho Ogunshola 2 , Omolara Baiyegunhi 2 , Nikoshia Mewalal 2 , Amber Moodley 2 , Krista Dong 1 , Thumbi Ndung’u 2 , Bruce D. Walker 1 1 Ragon Inst of MGH, MIT and Harvard, Cambridge, MA, USA, 2 Univ of KwaZulu Natal, Durban, South Africa 267 RESIDENTMEMORY CD8+T CELLS FORMTHE FRONT-LINE DEFENSE INHIV-INFECTED LYMPHNODES Marcus Buggert 1 , Lalit Beura 2 , Son Nguyen 1 , David Canaday 3 , Ali Naji 4 , Constantinos Petrovas 5 , Gustavo Reyes-Terán 6 , Steven G. Deeks 7 , David Masopust 2 , Michael R. Betts 1 1 Univ of Pennsylvania, Philadelphia, PA, USA, 2 Univ of Minnesota, Minneapolis, MN, USA, 3 Case Western Reserve Univ, Cleveland, OH, USA, 4 Hosp of the Univ of Pennsylvania, Philadelphia, PA, USA, 5 NIH, Bethesda, MD, USA, 6 Rsr Cntr in Infectious Diseases, Mexico City, Mexico, 7 Univ of California San Francisco, San Francisco, CA, USA 268 HIV-1 ESCAPE FROMCD8+CYTOTOXIC T-LYMPHOCYTES DEFINED AT CLONAL RESOLUTION Aleksandr Gorin , Yushen Du, Ren Sun, Otto Yang Univ of California Los Angeles, Los Angeles, CA, USA 269 INVESTIGATING THE ROLE OF TCR STRUCTURE IN FUNCTIONAL ACTIVITY OF HIV-SPECIFIC CTLs Nina C. Flerin 1 , Tynisha Glover 1 , Huabiao Chen 2 , Jianhua Zheng 1 , Harris Goldstein 1 1 Albert Einstein Coll of Med, Bronx, NY, USA, 2 Ragon Inst of Massachusetts General Hosp, Cambridge, MA, USA

Oral Sessions • Tuesday

CROI 2017 38